ID

22831

Beschreibung

Fulvestrant in Hormone Refractory Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00476645

Link

https://clinicaltrials.gov/show/NCT00476645

Stichworte

Versionen (1)
  1. 12.06.17 12.06.17 -
Hochgeladen am

12. Juni 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Prostatic Neoplasms NCT00476645

Englisch

Eligibility Prostatic Neoplasms NCT00476645

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
must give signed written informed consent
Beschreibung

Informed Consent

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
must be of age 18 years or older
Beschreibung

Age

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
histologically confirmed adenocarcinoma of the prostate
Beschreibung

Adenocarcinoma of prostate

Datentyp

boolean

Alias
UMLS CUI [1]
C0007112
must be currently receiving lhrh agonists and have castrate levels of testosterone or have had an orchiectomy
Beschreibung

Luteinizing Hormone-releasing Hormone Agonist | Testosterone measurement | Orchiectomy

Datentyp

boolean

Alias
UMLS CUI [1]
C1518041
UMLS CUI [2]
C0523912
UMLS CUI [3]
C0029189
must have had rise in psa despite anti-androgen withdrawal
Beschreibung

Raised prostate specific antigen | Androgen Antagonists Withdrawal

Datentyp

boolean

Alias
UMLS CUI [1]
C0178415
UMLS CUI [2,1]
C0002842
UMLS CUI [2,2]
C2349954
must exhibit two consecutive rises in psa after the last hormonal manipulation
Beschreibung

Raised prostate specific antigen Quantity Post Hormone Therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0178415
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0687676
UMLS CUI [1,4]
C0279025
minimum psa > 5mg/dl
Beschreibung

Prostate-Specific Antigen Minimum

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0138741
UMLS CUI [1,2]
C1524031
kps > 80%
Beschreibung

Karnofsky Performance Status

Datentyp

boolean

Alias
UMLS CUI [1]
C0206065
up to one prior chemotherapy treatments allowed
Beschreibung

Chemotherapy Quantity

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0392920
UMLS CUI [1,2]
C1265611
life expectancy of greater than 6 months
Beschreibung

Life Expectancy

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
concomitant hormonal therapy other than an lhrh
Beschreibung

Hormone Therapy | LHRH

Datentyp

boolean

Alias
UMLS CUI [1]
C0279025
UMLS CUI [2]
C0023610
noncompliance
Beschreibung

Non-compliance

Datentyp

boolean

Alias
UMLS CUI [1]
C0457432
platelets less than 100 x 10e9 /l
Beschreibung

Platelet Count measurement

Datentyp

boolean

Alias
UMLS CUI [1]
C0032181
international normalization ratio (inr) greater than 1.6
Beschreibung

International Normalized Ratio

Datentyp

boolean

Alias
UMLS CUI [1]
C0525032
total bilirubin greater than 1.5 x ulrr
Beschreibung

Elevated total bilirubin

Datentyp

boolean

Alias
UMLS CUI [1]
C0741494
alt or ast greater than 2.5 x ulrr if no demonstrable liver metastases or greater than 5.0 x ulrr in presence of liver metastases
Beschreibung

Alanine aminotransferase increased | Aspartate aminotransferase increased | Secondary malignant neoplasm of liver

Datentyp

boolean

Alias
UMLS CUI [1]
C0151905
UMLS CUI [2]
C0151904
UMLS CUI [3]
C0494165
history of bleeding diathesis (ie, disseminated intravascular coagulation [dic], clotting factor deficiency)
Beschreibung

Bleeding tendency | Disseminated Intravascular Coagulation | Clotting factor deficiency

Datentyp

boolean

Alias
UMLS CUI [1]
C1458140
UMLS CUI [2]
C0012739
UMLS CUI [3]
C0272315
history of long-term anticoagulant therapy (other than antiplatelet therapy)
Beschreibung

Anticoagulant therapy Long-term | Antiplatelet therapy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0150457
UMLS CUI [1,2]
C0443252
UMLS CUI [2]
C1096021
history of hypersensitivity to active or inactive excipients of fulvestrant (ie, castor oil or mannitol)
Beschreibung

Hypersensitivity Fulvestrant Excipient | Hypersensitivity Fulvestrant inactive ingredient | Castor oil allergy | Mannitol allergy

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0935916
UMLS CUI [1,3]
C0015237
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0935916
UMLS CUI [2,3]
C1552019
UMLS CUI [3]
C0571232
UMLS CUI [4]
C0571922
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Prostatic Neoplasms NCT00476645

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Informed Consent
Item
must give signed written informed consent
boolean
C0021430 (UMLS CUI [1])
Age
Item
must be of age 18 years or older
boolean
C0001779 (UMLS CUI [1])
Adenocarcinoma of prostate
Item
histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Luteinizing Hormone-releasing Hormone Agonist | Testosterone measurement | Orchiectomy
Item
must be currently receiving lhrh agonists and have castrate levels of testosterone or have had an orchiectomy
boolean
C1518041 (UMLS CUI [1])
C0523912 (UMLS CUI [2])
C0029189 (UMLS CUI [3])
Raised prostate specific antigen | Androgen Antagonists Withdrawal
Item
must have had rise in psa despite anti-androgen withdrawal
boolean
C0178415 (UMLS CUI [1])
C0002842 (UMLS CUI [2,1])
C2349954 (UMLS CUI [2,2])
Raised prostate specific antigen Quantity Post Hormone Therapy
Item
must exhibit two consecutive rises in psa after the last hormonal manipulation
boolean
C0178415 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0687676 (UMLS CUI [1,3])
C0279025 (UMLS CUI [1,4])
Prostate-Specific Antigen Minimum
Item
minimum psa > 5mg/dl
boolean
C0138741 (UMLS CUI [1,1])
C1524031 (UMLS CUI [1,2])
Karnofsky Performance Status
Item
kps > 80%
boolean
C0206065 (UMLS CUI [1])
Chemotherapy Quantity
Item
up to one prior chemotherapy treatments allowed
boolean
C0392920 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Life Expectancy
Item
life expectancy of greater than 6 months
boolean
C0023671 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Hormone Therapy | LHRH
Item
concomitant hormonal therapy other than an lhrh
boolean
C0279025 (UMLS CUI [1])
C0023610 (UMLS CUI [2])
Non-compliance
Item
noncompliance
boolean
C0457432 (UMLS CUI [1])
Platelet Count measurement
Item
platelets less than 100 x 10e9 /l
boolean
C0032181 (UMLS CUI [1])
International Normalized Ratio
Item
international normalization ratio (inr) greater than 1.6
boolean
C0525032 (UMLS CUI [1])
Elevated total bilirubin
Item
total bilirubin greater than 1.5 x ulrr
boolean
C0741494 (UMLS CUI [1])
Alanine aminotransferase increased | Aspartate aminotransferase increased | Secondary malignant neoplasm of liver
Item
alt or ast greater than 2.5 x ulrr if no demonstrable liver metastases or greater than 5.0 x ulrr in presence of liver metastases
boolean
C0151905 (UMLS CUI [1])
C0151904 (UMLS CUI [2])
C0494165 (UMLS CUI [3])
Bleeding tendency | Disseminated Intravascular Coagulation | Clotting factor deficiency
Item
history of bleeding diathesis (ie, disseminated intravascular coagulation [dic], clotting factor deficiency)
boolean
C1458140 (UMLS CUI [1])
C0012739 (UMLS CUI [2])
C0272315 (UMLS CUI [3])
Anticoagulant therapy Long-term | Antiplatelet therapy
Item
history of long-term anticoagulant therapy (other than antiplatelet therapy)
boolean
C0150457 (UMLS CUI [1,1])
C0443252 (UMLS CUI [1,2])
C1096021 (UMLS CUI [2])
Hypersensitivity Fulvestrant Excipient | Hypersensitivity Fulvestrant inactive ingredient | Castor oil allergy | Mannitol allergy
Item
history of hypersensitivity to active or inactive excipients of fulvestrant (ie, castor oil or mannitol)
boolean
C0020517 (UMLS CUI [1,1])
C0935916 (UMLS CUI [1,2])
C0015237 (UMLS CUI [1,3])
C0020517 (UMLS CUI [2,1])
C0935916 (UMLS CUI [2,2])
C1552019 (UMLS CUI [2,3])
C0571232 (UMLS CUI [3])
C0571922 (UMLS CUI [4])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video